Ground-breaking work creates novel oil-in-water nanoemulsions
New innovation has considerable potential to be used as a new environmentally friendly matrix for the microencapsulation and controlled release of a wide range of actives.
Particle Technology is an important discipline that underpins many industrial sectors, including biomedical applications, latex paints and coatings, engine oil additives, viscosity modifiers and emulsion stabilisation. Steve Armes, Professor of Polymer and Colloid Chemistry at the University of Sheffield, is one of the UK's leading experts in particle science and technology, with more than 30 years of research experience in this field. In particular, he designs a wide range of microscopic polymer particles on the nanoscale.
Professor Steve Armes said: "It is well known that oil and water do not mix. Similarly, the incorporation of oil droplets within inorganic crystals is highly counter-intuitive because there is a large difference in surface energy for these two components. Our new occlusion protocol, developed using the high-pressure LV-1 microfluidizer, has enabled either oil-soluble dyes or oil-dispersible hydrophobic nanoparticles to be incorporated for the first time within host crystals. This exciting new innovation has considerable potential to be used as a new environmentally friendly matrix for the microencapsulation and controlled release of a wide range of actives for various commercial applications. In view of this, we have filed a preliminary patent application to protect the IP associated with our work.
Professor Ames added: “We are indebted to the excellent technical support provided by Analytik, which has enabled us to fully exploit the high-pressure LV-1 Microfluidizer for the production of well-defined nanoemulsions. We will be seeking their support and advice in the future as we seek to extend our studies to include water-in-oil nanoemulsions.”
The LV1 Microfluidizer is a high shear homogeniser which brings outstanding processing capabilities to samples as small as 1 mL. The LV1 has been designed to achieve operating pressures up to 30,000 psi for samples ranging from 1-6 mL. Using proprietary fixed-geometry interaction chamber technology, the LV1 is capable of processing a wide variety of fluids such as oil-in-water emulsions, solids-in-liquid suspensions, and cells, including the most difficult yeasts and plant cells, in as few as 1-2 passes. What's more, the process is repeatable and is guaranteed to scale up to pilot and/or production volumes.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.